Sponsor of the Day:
Jerkmate
https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-nivolumab-ipilimumab-dmmr-colorectal-cancer
Immunotherapy Combo Approved for dMMR Colorectal Cancer - NCI
FDA approved the combination of Opdivo and Yervoy as an initial treatment for advanced colorectal tumors classified as MSI-H or dMMR.
colorectal cancerimmunotherapycomboapproveddmmr
https://oncodaily.com/new-paper-alert/keynote-158-pembrolizumab-gliomas
KEYNOTE-158: Pembrolizumab in MSI-H/dMMR Gliomas
Apr 6, 2026 - KEYNOTE-158 shows pembrolizumab has limited but durable activity in MSI-H/dMMR recurrent gliomas, with manageable safety.
msi h dmmrkeynote158pembrolizumabgliomas
https://www.healthday.com/healthpro-news/cancer/addition-of-atezolizumab-to-mfolfox6-ups-dfs-in-stage-iii-dmmr-colon-cancer
Atezolizumab Plus mFOLFOX Boosts DFS in Stage III dMMR Colon Cancer
Apr 3, 2026 - For patients with stage III mismatch repair-deficient colon cancer, the addition of the anti-programmed death ligand 1 agent atezolizumab to a modified regimen...
stage iiicolon cancerplusboostsdfs
https://www.keytruda.com/msi-h-dmmr-colorectal-cancer/
Advanced MSI-H/dMMR Colorectal Cancer (CRC)
Learn about immunotherapy treatment options for advanced MSI-H/dMMR colorectal cancer (CRC). Review clinical trial data for KEYTRUDA® (pembrolizumab) and...
msi h dmmrcolorectal canceradvancedcrc
https://www.oncologyeducation.com/videos/management-of-msi-h-dmmr-metastatic-colorectal-cancer/
Management of MSI-H/dMMR Metastatic Colorectal Cancer - OncologyEducation
Dec 3, 2025 - test Studies/trials discussed: Abstract #3501 – Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite...
msi h dmmrmetastatic colorectal cancermanagementoncologyeducation